The launch of Heme Libra, a 28-day hemophilia treatment, revealed a key challenge: patients accustomed to daily infusions were scared to trust the new, infrequent therapy. This shows that marketing truly disruptive products requires building trust and overcoming ingrained user habits, going beyond just demonstrating clinical superiority.

The word "virus" has deeply negative connotations. To successfully commercialize gene therapies that use viral delivery mechanisms, the industry needs a new, more scientific-sounding name—much like "GLP-1 peptide" was used instead of "Gila monster venom" for weight-loss drugs—to make it palatable to the public.

Beyond clinical efficacy, patient experience is a key differentiator. Patients strongly prefer single-administration ("one and done") gene therapies over treatments requiring regular injections. This is due to the cumulative stress, cost, and logistical burden of lifelong, recurring treatments, which directly informs therapeutic modality choice.

Consumer fear of GMOs is entrenched and funded, making education efforts ineffective. A better strategy is to use newer technologies like AI-driven breeding or CRISPR to achieve the same goals without triggering irrational consumer backlash, effectively sidestepping the debate.

To commercialize AI-designed viruses for medical treatments like gene therapy, the industry must overcome the term's negative public perception. A rebrand, similar to how "peptide" made GLP-1 drugs more palatable than "lizard venom," is crucial for widespread adoption and avoiding fear-based backlash.

Contrary to common belief, manufacturing costs for gene therapies are becoming manageable and approaching those of biologics. The real bottleneck preventing their use in broader diseases is the need to optimize the 'clunky' delivery vectors for better targeting and safety.

Recursion's CEO suggests communicating biotech's complexity by framing it as exploring a system we didn't design, unlike engineering. This humility-based analogy helps manage public expectations and explains the industry's long, non-linear timelines, fostering trust by highlighting the immense difficulty of decoding biology.

While "programmable medicine" excites investors, it creates fear among patients, evoking images of being chipped or controlled. To build public trust, biotech communication must pivot from technological coolness to the core patient needs: safety and efficacy.

Public resistance to frontier tech like AI and genetics is driven by abstract sci-fi narratives. The most effective antidote is direct product experience. Using ChatGPT makes 'Terminator' seem ridiculous, just as seeing embryo selection software demystifies the 'Gattaca' narrative.